Proof of concept and mechanisms for DPP4-dependent glucose control in humans A crossover, placebo-controlled, clinical trial was undertaken in 93 patients with type 2 diabetes previously controlled with diet and exercise, baseline glycated hemoglobin (HbA1c) 7.4%, treated with 100 mg three times daily or 150 mg twice daily with the DPP4 inhibitor, 1-[[[2-[(5-cyanopyridin-2-yl)amino]eth-yl]amino]acetyl]-2-cyano-(S)-pyrrolidine (NVP DPP728) for 4 weeks
In our clinic, focusing on the lowest possible dose for weight loss helps to mitigate these side effects
Kalc zm Deildir : lalar yaam tarz alkanlklarn kalc olarak deitirmez
These differences may also explain differences in gastrointestinal adverse reactions, such as nausea and vomiting, which are common with GLP-1RAs but typically diminish over time [127, 128]
Metabolic Effects of an Oral Glucose Tolerance Test Compared to the Mixed Meal Tolerance Tests: A Narrative Review